

ANNOUNCEMENT NO. 225

13 July 2022

Media coverage of disclosure of inside information

There has been coverage in the media today of a case concerning disclosure of inside information about ChemoMetec A/S.

The coverage has taken place in connection with the verdict in a case, which concerns unlawful disclosure of inside information regarding an impending positive company announcement from ChemoMetec A/S.

The disclosure took place after the closure of Nasdaq Copenhagen on 17 March 2021 by CEO Steen Søndergaard's wife and relates to an upward adjustment of the company's guidance, which was announced before the stock exchange opened the following day.

Neither ChemoMetec A/S nor Steen Søndergaard has been a party to the case.

Steen Søndergaard and his wife have not owned or own shares in ChemoMetec A/S for which reason they have not been able to obtain a financial gain from the disclosure of information.

Steen Søndergaard has not been aware of the wife's disclosure of information, and the Board of Directors continues to have full confidence in the CEO.

ChemoMetec A/S has no further comments on the matter.

For further information

Chairman of the board Niels Thestrup, ChemoMetec A/S

Phone: (+45) 3370 2000

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com